Blood Based Biomarkers Market Anticipated To Witness Robust Growth, Surpassing 41.55 Billion By 2029

Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.

What Is the Current Blood Based Biomarkers Market Size and Its Estimated Growth Rate?
The market size for blood-based biomarkers has significantly expanded in recent years. Forecasts suggest that it will increase from $23.13 billion in 2024 to $26.06 billion in 2025, with a compound annual growth rate (CAGR) of 12.6%. Several factors have contributed to the growth seen in the historical period, including the global increase in cancer cases, the growing use of personalized medicine, enhanced investment in biomarker research, the growth of clinical trials that utilise biomarkers, and an increase in the approval of companion diagnostics.

Expectations suggest that the market size for blood-based biomarkers will experience swift expansion in the foroming years, growing to a projected value of $41.55 billion by 2029 with a compound annual growth rate (CAGR) of 12.4%. This projected growth within the forecast timeframe can be credited to numerous factors, including the integration of AI and machine learning into biomarker analysis, the rising demand for early detection of diseases, advancements in telemedicine and remote diagnostics, an increasing prevalence of chronic ailments, and heightened awareness of health among consumers. The forecast period also anticipates prominent trends such as AI-managed biomarker identification, progress in liquid biopsies, the incorporation of multi-omics, the development of point-of-care (POC) testing apparatus, and innovative strides in next-generation sequencing (NGS).

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/customise?id=24176&type=smp

How Are Emerging Segments Shaping the Blood Based Biomarkers Market Landscape?
The blood based biomarkers market covered in this report is segmented -

1) By Type: Genetic Biomarkers, Protein Biomarkers, Metabolic Biomarkers, Cell-Based Biomarkers, Epigenetic Biomarkers
2) By Technology: Next-Generation Sequencing, Polymerase Chain Reaction, Immunoassays, Mass Spectrometry, Other Technologies
3) By Application: Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases, Other Applications
4) By End Users: Hospitals And Clinics, Diagnostic Laboratories, Research And Academic Institutes, Other End Users

Subsegments:

1) By Genetic Biomarkers: Deoxyribonucleic Acid (DNA) Mutations, Ribonucleic Acid (RNA) Expression Profiles, Single Nucleotide Polymorphisms (SNPs), Copy Number Variations (CNVs), Gene Fusions
2) By Protein Biomarkers: Enzymes, Hormones, Cytokines, Tumor Markers, Acute Phase Proteins
3) By Metabolic Biomarkers: Lipid Profiles, Amino Acid Levels, Glucose And Lactate Levels, Organic Acids, Metabolite Panels
4) By Cell-Based Biomarkers: Circulating Tumor Cells (CTCs), Immune Cell Profiling, Stem Cells, Platelets, Endothelial Cells
5) By Epigenetic Biomarkers: Deoxyribonucleic Acid (DNA) Methylation Patterns, Histone Modifications, Non-Coding Ribonucleic Acid (RNA), Chromatin Accessibility, Epigenetic Enzyme Activity

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24176&type=smp

Which Growth Factors Are Influencing Blood Based Biomarkers Market Expansion?
The escalation in instances of cardiovascular illnesses is anticipated to stimulate the expansion of the blood-based biomarkers market in the future. These diseases encompass a variety of ailments that impact the heart and blood vessels, such as coronary artery disease, heart failure, and stroke. The upsurge in these ailments is primarily accountable to escalating risk factors like poor eating habits and increasing instances of obesity. Blood-based biomarkers serve a crucial role in diagnosing and keeping track of cardiovascular illnesses by offering insights into the progression of the disease, risk evaluation, and response to treatment via detectable substances in the blood. For example, in September 2024, the National Center for Biotechnology Information, a government agency in the US, revealed a global health research initiative. The predictions displayed a 90% surge in the prevalence of cardiovascular diseases between 2025 and 2050, with an estimated 35.6 million cardiovascular fatalities by 2050. As such, the escalating instances of cardiovascular diseases are fueling the expansion of the blood-based biomarkers market.

Who Are the Dominant Players Across Different Blood Based Biomarkers Market Segments?
Major companies operating in the blood based biomarkers market are Siemens Healthineers AG, Agilent Technologies Inc, Eisai Co Ltd, Sysmex Corporation, Exact Sciences Corporation, Guardant Health, Quanterix Corporation, Illumina Inc, QIAGEN NV, GENFIT, Foundation Medicine Inc, Adaptive Biotechnologies Corporation, GRAIL LLC, Biodesix Inc, Cleveland Diagnostics Inc, Creative Diagnostics, Epigenomics AG, C2N Diagnostics, Diadem srl, Proteomedix AG

What Blood Based Biomarkers Market Trends Are Gaining Traction Across Different Segments?
Leading firms in the blood-based biomarkers sector are concentrating on technological innovations, such as highly accurate blood biomarker examinations, to assist doctors in diagnosing Alzheimer's disease. A highly accurate blood biomarker test is a diagnostic instrument that uses particular biomarkers found in the blood to discover diseases or track health conditions, providing a high degree of accuracy and dependability. For example, Quanterix, a life sciences firm based in the United States, introduced a highly accurate blood biomarker test named LucentAD p-Tau 217 in October 2023. This test is designed to help physicians diagnose Alzheimer's disease in cognitively impaired adults. It quantifies the phosphorylated tau protein at threonine 217 (p-Tau 217), a biomarker that is strongly linked with Alzheimer's disease pathology, especially the accumulation of amyloid in the brain. The LucentAD p-Tau 217 test achieves over 90% accuracy and fulfills strict diagnostic standards. This test is designed to be used alongside other diagnostic instruments, not as a standalone test.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/blood-based-biomarkers-global-market-report

Which Geographic Regions Are Expected to Dominate the Blood Based Biomarkers Market in the Coming Years?
North America was the largest region in the blood-based biomarkers market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the blood based biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Blood Based Biomarkers Market?
2. What is the CAGR expected in the Blood Based Biomarkers Market?
3. What Are the Key Innovations Transforming the Blood Based Biomarkers Industry?
4. Which Region Is Leading the Blood Based Biomarkers Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.